Publicaciones en colaboración con investigadores/as de University College London (20)

2022

  1. Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand

    Antiviral Therapy, Vol. 27, Núm. 3

2020

  1. Clinical outcomes of a zika virus mother–child pair cohort in Spain

    Pathogens, Vol. 9, Núm. 5

2018

  1. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial

    PLoS ONE, Vol. 13, Núm. 4

2017

  1. Erratum to: Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand (European Journal of Clinical Pharmacology, (2017), 73, 4, (463-468), 10.1007/s00228-016-2182-2)

    European Journal of Clinical Pharmacology

  2. Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand

    European Journal of Clinical Pharmacology, Vol. 73, Núm. 4, pp. 1-6

2016

  1. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): An open-label, parallel-group, randomised controlled trial

    The Lancet Infectious Diseases, Vol. 16, Núm. 2, pp. 169-179

  2. Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption

    AIDS, Vol. 30, Núm. 7, pp. 1075-1081

  3. Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project

    BMC Infectious Diseases, Vol. 16, Núm. 1

2014

  1. Post-licensing safety of fosamprenavir in HIV-infected children in Europe

    Pharmacoepidemiology and Drug Safety, Vol. 23, Núm. 3, pp. 321-325

2013

  1. Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children

    AIDS and Behavior, Vol. 17, Núm. 1, pp. 193-202

  2. Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

    PLoS Medicine, Vol. 10, Núm. 9

  3. The incidence of AIDS-defining illnesses at a current CD4 count ≥200 cells/μL in the post-combination antiretroviral therapy era

    Clinical Infectious Diseases, Vol. 57, Núm. 7, pp. 1038-1047

  4. Use of combination neonatal prophylaxis for the prevention of mother-to-child transmission of HIV infection in European high-risk infants

    AIDS, Vol. 27, Núm. 6, pp. 991-1000

2012

  1. CD4 cell count and the risk of AIDS or death in HIV-infected adults on combination antiretroviral therapy with a suppressed viral load: A longitudinal cohort study from COHERE

    PLoS Medicine, Vol. 9, Núm. 3

  2. Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: A cohort study

    The Lancet Infectious Diseases, Vol. 12, Núm. 2, pp. 119-127

2011

  1. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: An open-label, randomised phase 2/3 trial

    The Lancet Infectious Diseases, Vol. 11, Núm. 4, pp. 273-283

  2. Risk of triple-class virological failure in children with HIV: A retrospective cohort study

    The Lancet, Vol. 377, Núm. 9777, pp. 1580-1587

2010

  1. Is it safe to discontinue primary pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 Cell Count <200 Cells/μL?

    Clinical Infectious Diseases, Vol. 51, Núm. 5, pp. 611-619

2009

  1. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy

    AIDS, Vol. 23, Núm. 15, pp. 2029-2037

2008

  1. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children

    Clinical Infectious Diseases, Vol. 46, Núm. 10, pp. 1601-1608